Adjuvant/Curative/Neo-adjuvant Bladder/Urothelial Cancer
Regimens
The following table lists the evidence-informed regimens (both IV and non-IV) for bladder/urothelial
cancer used in the adjuvant/curative/neo-adjuvant setting. It is expected that the prescribing oncologist
will select the regimen from the list of evidence-informed regimens that is most appropriate for their
patient taking account of a variety of disease-specific and patient-related factors.
Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the
regimen and treatment intent.
Bladder/Urothelial Cancer
Regimen Code
Regimen Abstract
CISP
CISplatin 50-100 mg/m² IV day 1.
Q21 days
CISP(RT)
CISplatin 50-100 mg/m² IV day 1.
Q14 days
Concurrent with radiotherapy
CISP(RT-W)
CISplatin 40 mg/m² IV day 1
Weekly with concurrent radiotherapy
CISPETOP(3D)
CISplatin 25 mg/m² IV days 1- 3;
Etoposide 100 mg/m² IV days 1- 3 days.
Q21 days
For Small Cell Carcinoma
CISPFU
CISplatin 70-100 mg/m² IV day 1 (dose may be divided over 3-4 days);
Fluorouracil 1000 mg/m²/day CIV daily days 1-4.
Q21-28 days
CISPGEMC
CISplatin 70 mg/m² IV day 1;
Gemcitabine 1000 mg/m² IV days 1, 8, 15.
Q28 days
Alternative schedule:
CISplatin 70 mg/m² IV day 1;
Gemcitabine 1000-1250 mg/m² IV days 1, 8.
Q21 days
CISPGEMC(W)
CISplatin 35 mg/m2 days 1, 8;
Gemcitabine 1000 mg/m2 days 1, 8.
Q21 days
Bladder/Urothelial Cancer
Regimen Code
Regimen Abstract
2
CISPGEMCPACL
CISplatin 70 mg/m day 1;
Gemcitabine 1000 mg/m2 days 1, 8;
PACLitaxel 80 mg/m2 days 1, 8.
Q21 days
CMV
CISplatin 70-100 mg/m² IV day 2;
Methotrexate 30 mg/m² IV days 1, 8;
vinBLAStine 4 mg/m² IV days 1, 8.
Q21 days
CRBP
CARBOplatin AUC 5-6 IV day 1.
Q21 days
CRBP(RT)
CARBOplatin AUC 1.5 IV day 1.
Weekly with concurrent radiotherapy
CRBPETOP
CARBOplatin AUC 5 IV day 1;
Etoposide 100 mg/m² IV days 1-3.
Q21 days
For small cell carcinoma
CRBPGEMC
CARBOplatin AUC 5-6 IV day 1;
Gemcitabine 1000 mg/m² IV days 1, 8.
Q21 days
FUMTMC(RT)
Fluorouracil 500 mg/m²/day CIV over 24 hours, days 1-5, and 16-20 of radiation
treatment (weeks 1 and 4);
Mitomycin 12 mg/m² IV day 1
Concurrent with radiation over 5 weeks
Methotrexate 30 mg/m² IV days 1, 15, 22;
vinBLAStine 3 mg/m² IV days 2, 15, 22;
DOXOrubicin 30 mg/m² IV day 2;
CISplatin 70 mg/m² IV day 2.
Q28 days
MVAC
MVAC(HD)
Methotrexate 30 mg/m² IV day 1;
vinBLAStine 3 mg/m² IV day 2;
DOXOrubicin 30 mg/m² IV day 2;
CISplatin 70 mg/m² IV day 2.
Q14 days
Last Updated: January 2016